Liminal Biosciences Is A Clinical Stage Biopharmaceutical Company Based In Lavalquebecwith Additional Operations In Bellevilleontarioand Cambridgeukthe Company Specializes In Discovering And Developing Novel Small Molecule Therapeutics That Target G Protein Coupled Receptorgpcrpathwaysliminal Focuses On Addressing Unmet Medical Needs In Metabolicinflammatoryand Fibrotic Diseasesin 2021The Company Shifted Its Strategy To Concentrate Solely On Its Small Molecule Pipeline After Divesting Its Plasma Derived Therapeutics Business Liminal Employs An Integrated Drug Discovery Platform That Combines Medicinal Chemistry And Gpcr Biology To Design Proprietary Therapeuticsits Product Pipeline Includes A Lead Candidatelmnl6511Which Is Advancing Toward Phase 1 Trials For Conditions Like Non Alcoholic Steatohepatitisnashand Inflammatory Bowel Diseaseibd The Company Is Also Developing Programs Targeting Eosinophil Mediated Diseases And Liver Safe Treatments For Type 2 Diabetesin September 2023Liminal Was Acquired By Structured Alpha Lpconsolidating Its Ownership And Management
